Antonio F. Santidrian, PharmD, Ph.D., promoted
to Chief Scientific Officer and Amish Patel, Ph.D., promoted to
Senior Vice President of Technical Operations
Alan Stewart appointed to Board of
Directors
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”),
a clinical-stage biotechnology company developing a new generation
of targeted immunotherapies, today announced two key promotions
from the clinical leadership team and the appointment of a new
Board Director. Antonio Santidrian, PharmD, Ph.D., previously
Senior Vice President, Global Head of Research and Development, has
been promoted to Chief Scientific Officer and Amish Patel, Ph.D.,
has been promoted to Senior Vice President of Technical Operations.
In addition, Alan Stewart, a Calidi advisor since 2020, has been
appointed to the Board of Directors. Mr. Stewart will replace Dr.
Heehyoung Lee as an independent Director and Chair of the Audit
Committee.
“I am delighted to announce the well-deserved promotions of Drs.
Santidrian and Patel, who have been instrumental in the development
and manufacturing of our differentiated cell-based delivery
platforms,” said Allan Camaisa, CEO and Chairman of the Board of
Calidi Biotherapeutics. “As CSO, Dr. Santidrian will continue to
apply his expertise in oncology and leadership in discovery, to
expand the potential of our novel technology. In Dr. Patel’s new
role, he will continue to innovate and accelerate Calidi’s leading
technical and manufacturing capabilities to drive the clinical
advancement of our assets. Alan Stewart’s previous role serving as
an advisor to Calidi, as well as his strong financial and capital
markets background, will be invaluable to us as a newly public
company. Lastly, I would like to thank Dr. Lee, one of Calidi’s
earliest investors, for her support and guidance over the last
three years and wish her well in her future endeavors.”
Antonio F. Santidrian, PharmD, Ph.D., previously served as
Senior Vice President, Global Head of Research and Development at
Calidi since September 2021. Dr. Santidrian has over 22 years of
experience in anti-cancer translational research and drug
development, and as Chief Scientific Officer will lead research and
development activities to fully leverage the potential of Calidi’s
Pipeline and first-in-class allogeneic stem cell-based delivery
platforms to provide a new generation of targeted and universal
cancer immunotherapies. Dr. Santidrian is co-inventor of Calidi’s
Supernova platform, a universal cell-based delivery platform
designed to protect, amplify, and potentiate oncolytic viruses to
enhance efficacy and improve patient safety. Before Calidi, Dr.
Santidrian led translational studies at The Scripps Research
Institute for several small molecule and biologic drugs treating
metastatic breast cancer. Dr. Santidrian worked closely on the
translational cancer studies for the development of ACADRA to treat
Chronic lymphocytic leukemia (CLL) at the University of Barcelona.
Dr. Santidrian is the recipient of a fellowship from the Ministry
of Science and Education (Spain), Susan G. Komen Breast cancer
foundation, and the August Pi I Sunyer Foundation. Dr. Santidrian
received a degree in Pharmacy (equivalent to the PharmD program)
from the University of Barcelona in 2001 and a Ph.D. in
biomedicine, specializing in anti-cancer therapies, in 2006 from
the University of Barcelona in Barcelona, Spain.
Amish Patel, Ph.D., previously served as Vice President of
Technical Operations since joining Calidi in August 2022. Dr. Patel
has over 19 years of global biopharma and biotech leadership
experience, providing strategic guidance throughout the entire
biologic product life cycle. Dr. Patel will be responsible for
overseeing global manufacturing, quality, and supply chain to
produce clinical and commercial therapies utilizing Calidi’s
innovative cell-based delivery of oncolytic viruses. Over the
course of his career, he has led the development of over 15 INDs,
two commercial product approvals, and numerous PAS submissions. He
was most recently the Senior Director of Product Development at
Emergent BioSolutions (formerly PaxVax, Inc., prior to
acquisition), where he successfully built and directed
cross-functional teams working on numerous technology platforms.
Prior to Emergent, Dr. Patel led the technical development of oral
insulin delivery technology at Ansun Biopharma and cell
transplantation therapy for patients with diabetes at MicroIslet
Inc. Dr. Patel also serves as a member of the Technical Activities
Committee of the National Institute for Innovation in Manufacturing
Biopharmaceuticals (NIIMBL) part of Manufacturing USA® which is
funded through U.S. Department of Commerce with significant
additional support from its members. He also serves ad hoc on a
scientific review panel at National Institutes of Health. Dr. Patel
received his Ph.D. in Engineering/Nanotechnology and M.S. in
Chemical Engineering from Louisiana Tech University specializing in
using nanotechnology tools for enzyme and DNA encapsulation and
delivery funded by a NASA grant. He has his Bachelor of Engineering
in Chemical from Poona University, India.
Alan Stewart has worked as an advisor to Calidi since 2020.
Currently, he serves as the Chief Financial Officer at
SoundThinking (formerly known as ShotSpotter Inc.). Prior to
joining SoundThinking, he served as Managing Director of RA Capital
Advisors, LLC, a private investment bank specializing in mergers
and acquisitions, private financings, and restructurings. In
addition to his experience in banking and private finance, Alan
served as the CEO of FIT Advisors, LLC, a boutique consulting firm
that offers temporary CFO services and worked with clients from
start-up ventures to large private companies. He currently serves
as a Director at Round Feather Inc. and Ravenswood Solutions Inc.
and was awarded CFO of the Year by the San Diego Business Journal
in both 2007 and 2013. In 2021, Mr. Stewart was one of the
Finalists (one of three) as CFO of the Year for Northern
California, including San Francisco and Silicon Valley. In 2023, he
was selected as one of San Francisco’s Top 25 CFOs and one of the
Top 10 Inspiring CFOs (C-Level Focus Magazine). Prior to his
business career, Mr. Stewart served over ten years as a submarine
nuclear engineer in the United States Navy. He received his B.S. in
Oceanography, with distinction, from the U.S. Naval Academy and his
M.B.A. from the Harvard Business School.
About Calidi Biotherapeutics:
Calidi Biotherapeutics (NYSE: CLDI) is a clinical-stage
immuno-oncology company with proprietary technology designed to arm
the immune system to fight cancer with a novel stem cell-based
therapy delivering a payload to target and kill tumor cells. Calidi
Biotherapeutics is advancing a potent allogeneic stem cell capable
of carrying an anti-tumor payload for use in multiple oncology
indications, including high-grade gliomas and solid tumors.
Calidi’s off-the-shelf, universal cell-based delivery platforms are
designed to protect, amplify, and potentiate oncolytic viruses
leading to enhanced efficacy and improved patient safety. This dual
approach can potentially treat, or even prevent, metastatic
disease. Calidi Biotherapeutics is headquartered in San Diego,
California. For more information, please visit
www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for
purposes of the “safe harbor” provisions under the United States
Private Securities Litigation Reform Act of 1995. Terms such as
“anticipates,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “might,” “plan,” “possible,”
“potential,” “predicts,” “project,” “should,” “towards,” “would” as
well as similar terms, are forward-looking in nature, but the
absence of these words does not mean that a statement is not
forward-looking. Any forward-looking statements contained in this
discussion are based on Calidi’s current expectations and beliefs
concerning future developments and their potential effects. There
can be no assurance that future developments affecting Calidi will
be those that it has anticipated. Any forward-looking statements
involve a number of risks, uncertainties (some of which are beyond
Calidi’s control) or other assumptions that may cause actual
results or performance to be materially different from those
expressed or implied by these forward-looking statements. Other
risks and uncertainties are set forth in the section entitled “Risk
Factors” and “Cautionary Note Regarding Forward-Looking Statements”
in the Form S-1 registration statement filed with the SEC and dated
October 6, 2023
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101761574/en/
For Media: Gwen Gordon gwen@gwengordonpr.com
For Investors: Stephen Jasper Gilmartin Group
stephen@gilmartinir.com
Calidi Biotherapeutics (AMEX:CLDI)
過去 株価チャート
から 2 2025 まで 3 2025
Calidi Biotherapeutics (AMEX:CLDI)
過去 株価チャート
から 3 2024 まで 3 2025
